Toggle light / dark theme

Japanese scientists have reported the first successful skin-to-eye stem cell transplant in humans, where stem cells derived from a patient’s skin were transplanted into her eye to partially restore lost vision.

The patient, a 70-year-old woman diagnosed with age-related macular degeneration (AMD) – the leading cause of vision impairment in older people – received the experimental treatment back in 2014 as part of a pilot study. Now, closing in on two years after the transplant took place, the scientists are sharing the results.

The researchers took a small piece of skin from her arm (4 mm in diameter) and modified its cells, effectively reprogramming them into induced pluripotent stem cells (iPSC).

Read more

Something so simple and finally done to help so many.

Beautiful


Researchers at the University of California said the new system dramatically improves the ability of people with limited sight to read books, menus, newspapers and emails.

The camera is not limited to text: its makers said it can also recognise faces and products.

Nice


A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment.

The study in rats showed transfer of a gene known as KCC2 into the spinal canal restored chloride levels gone awry after nerve injury. Results from the research at The University of Texas MD Anderson Cancer Center, were published in the May 5 online issue of Cell Reports.

The results also could have implications for treatment of chronic pain due to diabetic neuropathy and spinal cord injury since neuropathic pain caused by these conditions is associated with reduced KCC2 activity.

Ido Bachelet, Shawn Douglas and George Church filed a patent in 2011 for DNA origami devices useful in the targeted delivery of biologically active entities to specific cell populations.

This is the patent for the DNA nanorobot for molecular precise delivery of treatments to cells. This has been covered several times by Nextbigfuture

Their DNA origami device comprises a scaffold strand and a plurality of staple strands, wherein:

Read more

Using bacteria to aid in the design of superior biomedical implants capable of resisting colonization by infectious bugs.


Dr. Pushkar Lele, assistant professor in the Artie McFerrin Department of Chemical Engineering at Texas A&M University, is developing novel insights in cellular mechanics with bacteria to aid in the design of superior biomedical implants capable of resisting colonization by infectious bugs. Lele’s group also focuses on unraveling the fundamental principles underlying interactions in biological soft-matter to build bio-nanotechnology-based molecular machines. Lele’s lab currently focuses on a unique electric rotary device found in bacteria — the flagellar motor.

According to Lele, it is well established how motile bacteria employ flagellar motors to swim and respond to chemical stimulation. This allows bacteria to search for nutrients and evade harmful chemicals. However, in his recent work, Lele has now demonstrated that the motor is also sensitive to mechanical stimulation and identified the protein components responsible for the response. Sensing initiates a sensitive control of the assemblies of numerous proteins that combine to form the motor. Control over motor assemblies facilitates fine-tuning of cellular behavior and promotes chances of survival in a variety of environments.

“What is the sense of touch in a bacterium? It is likely that they employ appendages such as the flagella to detect solid substrates, analogous to our use of fingers,” Lele said. “How they recognize the substrate using the flagellum has been a long-standing question in biology with tremendous biomedical significance. Our findings have provided a handle on this important problem. We now know [how] the motor-components [are] involved in sensing the substrate [and] would like to know how these sensors trigger signaling networks that ultimately cause infections. “.

New cure for SMA?!


Spinal muscular atrophy (SMA) is a disease that causes progressive degeneration in the nerve cells that control muscles, thereby causing muscle weakness and eventually death. SMA affects approximately 200,000 people in the U.S., often children. Now, researchers at the University of Missouri are studying a subtype of SMA, spinal muscular atrophy with respiratory distress type 1 (SMARD1), and have developed a gene replacement therapy that can be used to treat and control the disease in the future.

SMARD1 is a rare genetic condition with high mortality rate that develops primarily between the ages of six weeks and six months. The condition targets the spinal cord and leads to atrophy of body muscles and paralysis of the diaphragm, which is responsible for breathing. As the disease progresses, children with a SMARD1 diagnosis become paralyzed and require continuous artificial ventilation. The average life expectancy of a child diagnosed with SMARD1 is 13 months. Currently, there is no cure or effective treatment for this disease.

“Monogenic diseases like SMARD1, a disease that is caused by one gene, are ideal for gene therapy since the goal of the therapy is to replace the missing or defective gene,” said Chris Lorson, an investigator in the Bond Life Sciences Center and a professor of veterinary pathobiology. “Our goals for this study were to develop a vector that would improve the outcomes of the disease and for the vector to be effective in a single dose.”

Read more